TotalMarketCap

Neurogene

NGNENasdaq CanadaHealth CareBiotechnology: Pharmaceutical Preparations

Market cap

$516.094 M

$25.79 -6.49%

Close of 6 Nov 2026

As of 6 Nov 2026, Neurogene (NGNE) has a market capitalization of $516.1M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$0.00

#3616 by revenue

Earnings

-$90.4M

Loss-making

Shares outstanding

20,011,382

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →
  1. #182Bicara TherapeuticsBCAX$542.6M
  2. #183Aclaris TherapeuticsACRS$529.9M
  3. #184NeurogeneNGNE$516.1M
  4. #185Climb BioCLYM$510.0M
  5. #186Faeth TherapeuticsFTH$509.9M

What if Neurogene were worth as much as…

Open the what-if tool →

Gold $28.2T

$1,411,041

Per share 54,713× higher

Bitcoin $1.53T

$76,348.95

Per share 2,960× higher

Apple $5.02T

$250,646.49

Per share 9,719× higher

Or at a round number

$1.00B$2.00B$5.00B$10.0B

Where these numbers come from

Share counts and financials for Neurogene are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.